|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000104221 |
Summary for BRF2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000104221 | Gene symbol | BRF2 |
| Gene name | BRF2 RNA polymerase III transcription initiation factor subunit | |
| HGNC | 17298 | |
| Entrez ID | 55290 | |
| Gene type | protein_coding | |
| Synonyms | BRF2|FLJ11052|BRFU|TFIIIB50 | |
| UniProtAcc | Q9HAW0 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for BRF2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| BRF2 | 7.37e+02 | 1.09e+00 | 1.73e-01 | 6.26e+00 | 3.89e-10 | 1.00e-09 | LUSC |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for BRF2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for BRF2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| HNSC | cg22871204 | chr8:37851387 | CGI:chr8:37849631-37849989 | promoter | 8.16e-01 | 9.40e-01 | -4.07e+00 | 4.73e-05 | 1.38e-04 | -1.24e-01 |
| LUSC | cg20466478 | chr8:37851091 | CGI:chr8:37849631-37849989 | promoter | 4.70e-01 | 8.49e-01 | -3.50e+00 | 4.58e-04 | 1.57e-03 | -3.79e-01 |
| LUSC | cg19904653 | chr8:37850174 | CGI:chr8:37849631-37849989 | promoter | 1.40e-01 | 2.69e-01 | -2.84e+00 | 4.51e-03 | 7.55e-03 | -1.29e-01 |
| LUSC | cg22871204 | chr8:37851387 | CGI:chr8:37849631-37849989 | promoter | 7.77e-01 | 9.45e-01 | -3.28e+00 | 1.04e-03 | 2.67e-03 | -1.67e-01 |
| BLCA | cg22871204 | chr8:37851387 | CGI:chr8:37849631-37849989 | promoter | 7.61e-01 | 9.38e-01 | -3.79e+00 | 1.50e-04 | 5.37e-04 | -1.77e-01 |
| LIHC | cg02894896 | chr8:37849203 | CGI:chr8:37849631-37849989 | promoter,gene body | 3.50e-01 | 4.69e-01 | -4.26e+00 | 2.04e-05 | 5.09e-05 | -1.19e-01 |
| LIHC | cg19904653 | chr8:37850174 | CGI:chr8:37849631-37849989 | promoter | 1.98e-01 | 3.00e-01 | -2.09e+00 | 3.67e-02 | 3.82e-02 | -1.02e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
Top |
Exon skipping events with PSI in TCGA for BRF2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for BRF2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for BRF2 |
| TFs related to BRF2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| ACC | MSX2 | BRF2 | 4.60e+00 | 9.80e-01 | 3.90e+00 | 1.54e-02 | Male-biased |
| ACC | SPI1 | BRF2 | 4.09e+00 | 9.82e-01 | 3.23e+00 | 7.66e-03 | Male-biased |
| ACC | SPIB | BRF2 | 4.14e+00 | 9.82e-01 | 3.31e+00 | 8.50e-03 | Male-biased |
| BLCA | BARX1 | BRF2 | 4.72e+00 | 9.93e-01 | 3.50e+00 | 2.50e-03 | Male-biased |
| BLCA | BCL6B | BRF2 | 4.37e+00 | 9.84e-01 | 3.50e+00 | 7.86e-03 | Male-biased |
| BLCA | ELF3 | BRF2 | 4.24e+00 | 9.89e-01 | 2.69e+00 | 7.82e-04 | Male-biased |
| BLCA | MSX1 | BRF2 | 4.58e+00 | 9.93e-01 | 3.12e+00 | 1.07e-03 | Male-biased |
| BLCA | MSX2 | BRF2 | 4.53e+00 | 9.93e-01 | 3.11e+00 | 1.24e-03 | Male-biased |
| BLCA | SOX8 | BRF2 | 4.28e+00 | 9.88e-01 | 3.07e+00 | 2.37e-03 | Male-biased |
| BLCA | TCF7L2 | BRF2 | 4.21e+00 | 9.81e-01 | 3.37e+00 | 8.22e-03 | Male-biased |
| BLCA | ZNF45 | BRF2 | 4.23e+00 | 9.85e-01 | 3.18e+00 | 4.15e-03 | Male-biased |
| BLCA | ZNF653 | BRF2 | 5.76e+00 | 9.84e-01 | 5.05e+00 | 1.47e-02 | Male-biased |
| BLCA | ZNF8 | BRF2 | 4.51e+00 | 9.88e-01 | 3.52e+00 | 5.18e-03 | Male-biased |
| BLCA | ZNF85 | BRF2 | 4.19e+00 | 9.86e-01 | 3.03e+00 | 2.78e-03 | Male-biased |
| MESO | BARX1 | BRF2 | 3.65e+00 | 3.84e-03 | 5.23e+00 | 9.94e-01 | Female-biased |
| MESO | ELF3 | BRF2 | 3.04e+00 | 7.58e-04 | 5.04e+00 | 9.96e-01 | Female-biased |
| MESO | ELK4 | BRF2 | 4.79e+00 | 9.86e-01 | 3.56e+00 | 9.40e-03 | Male-biased |
| MESO | GABPA | BRF2 | 4.69e+00 | 9.92e-01 | 3.14e+00 | 3.29e-03 | Male-biased |
| MESO | KLF2 | BRF2 | 3.86e+00 | 9.82e-01 | 1.80e+00 | 4.70e-04 | Male-biased |
| MESO | KLF6 | BRF2 | 3.97e+00 | 9.84e-01 | 2.18e+00 | 1.24e-03 | Male-biased |
| MESO | MSX1 | BRF2 | 3.26e+00 | 7.76e-04 | 5.26e+00 | 9.97e-01 | Female-biased |
| MESO | MSX2 | BRF2 | 3.23e+00 | 7.57e-04 | 5.24e+00 | 9.97e-01 | Female-biased |
| MESO | SOX8 | BRF2 | 3.26e+00 | 2.47e-03 | 4.96e+00 | 9.94e-01 | Female-biased |
| MESO | SPI1 | BRF2 | 2.67e+00 | 1.98e-03 | 4.41e+00 | 9.90e-01 | Female-biased |
| MESO | SPIB | BRF2 | 2.90e+00 | 3.91e-03 | 4.45e+00 | 9.88e-01 | Female-biased |
| MESO | SPIC | BRF2 | 2.99e+00 | 4.81e-03 | 4.49e+00 | 9.88e-01 | Female-biased |
| MESO | TCF4 | BRF2 | 3.28e+00 | 8.44e-03 | 4.60e+00 | 9.85e-01 | Female-biased |
| MESO | TCF7L2 | BRF2 | 3.45e+00 | 1.06e-02 | 4.70e+00 | 9.84e-01 | Female-biased |
| MESO | ZNF121 | BRF2 | 4.17e+00 | 9.86e-01 | 2.58e+00 | 2.60e-03 | Male-biased |
| MESO | ZNF181 | BRF2 | 4.15e+00 | 9.86e-01 | 2.60e+00 | 3.04e-03 | Male-biased |
| MESO | ZNF200 | BRF2 | 4.74e+00 | 9.90e-01 | 3.32e+00 | 4.96e-03 | Male-biased |
| MESO | ZNF33A | BRF2 | 4.20e+00 | 9.87e-01 | 2.61e+00 | 2.63e-03 | Male-biased |
| MESO | ZNF443 | BRF2 | 4.20e+00 | 9.83e-01 | 2.85e+00 | 6.15e-03 | Male-biased |
| MESO | ZNF45 | BRF2 | 3.36e+00 | 6.03e-03 | 4.79e+00 | 9.89e-01 | Female-biased |
| MESO | ZNF519 | BRF2 | 4.04e+00 | 9.86e-01 | 2.00e+00 | 5.16e-04 | Male-biased |
| MESO | ZNF653 | BRF2 | 4.92e+00 | 1.67e-02 | 6.04e+00 | 9.82e-01 | Female-biased |
| MESO | ZNF770 | BRF2 | 4.12e+00 | 9.88e-01 | 1.76e+00 | 1.69e-04 | Male-biased |
| MESO | ZNF774 | BRF2 | 3.82e+00 | 9.80e-01 | 1.83e+00 | 6.03e-04 | Male-biased |
| MESO | ZNF8 | BRF2 | 3.69e+00 | 1.09e-02 | 4.95e+00 | 9.85e-01 | Female-biased |
| MESO | ZNF85 | BRF2 | 3.26e+00 | 2.26e-03 | 4.98e+00 | 9.94e-01 | Female-biased |
| SARC | BARX1 | BRF2 | 4.58e+00 | 9.81e-01 | 4.06e+00 | 1.28e-02 | Male-biased |
| SARC | ELF3 | BRF2 | 4.16e+00 | 9.81e-01 | 3.52e+00 | 6.10e-03 | Male-biased |
| SARC | PRDM6 | BRF2 | 4.30e+00 | 9.83e-01 | 3.67e+00 | 6.42e-03 | Male-biased |
| SARC | ZNF22 | BRF2 | 4.35e+00 | 9.81e-01 | 3.79e+00 | 9.76e-03 | Male-biased |
| SARC | ZNF225 | BRF2 | 4.32e+00 | 9.85e-01 | 3.66e+00 | 5.55e-03 | Male-biased |
| SARC | ZNF235 | BRF2 | 4.57e+00 | 9.87e-01 | 3.94e+00 | 6.79e-03 | Male-biased |
| SARC | ZNF287 | BRF2 | 4.42e+00 | 9.86e-01 | 3.78e+00 | 6.07e-03 | Male-biased |
| SARC | ZNF384 | BRF2 | 4.14e+00 | 9.80e-01 | 3.51e+00 | 6.62e-03 | Male-biased |
| SARC | ZNF487 | BRF2 | 4.42e+00 | 9.84e-01 | 3.81e+00 | 7.36e-03 | Male-biased |
| SARC | ZNF492 | BRF2 | 4.24e+00 | 9.82e-01 | 3.62e+00 | 6.89e-03 | Male-biased |
| SARC | ZNF613 | BRF2 | 4.21e+00 | 9.81e-01 | 3.59e+00 | 7.01e-03 | Male-biased |
| SARC | ZNF98 | BRF2 | 4.32e+00 | 9.82e-01 | 3.73e+00 | 8.21e-03 | Male-biased |
| BRF2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for BRF2 |
| RBPs related to ES in BRF2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| THYM | SRSF9 | exon_skip_489136 | 8.32e+00 | 9.85e-01 | 7.98e+00 | 7.68e-03 | Male-biased |
| COAD | SRSF9 | exon_skip_489136 | 7.91e+00 | 1.17e-02 | 8.23e+00 | 9.81e-01 | Female-biased |
| BRCA | ZNF638 | exon_skip_489144 | 1.50e+01 | 9.97e-01 | 1.42e+01 | 3.04e-03 | Male-biased |
| PCPG | ZNF638 | exon_skip_489144 | 1.45e+01 | 8.79e-04 | 1.51e+01 | 9.99e-01 | Female-biased |
| MESO | SRSF9 | exon_skip_489136 | 8.27e+00 | 9.85e-01 | 7.89e+00 | 7.38e-03 | Male-biased |
| PAAD | ZNF638 | exon_skip_489144 | 1.44e+01 | 4.53e-04 | 1.49e+01 | 9.99e-01 | Female-biased |
| SKCM | SRSF9 | exon_skip_489136 | 7.91e+00 | 9.00e-03 | 8.27e+00 | 9.84e-01 | Female-biased |
| SARC | ZNF638 | exon_skip_489144 | 1.46e+01 | 1.19e-03 | 1.52e+01 | 9.99e-01 | Female-biased |
| BRF2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs76863471 | chr8:40474758:C:T | - | 0.128906344727889 | 0.020956333136641 | SARC | Female-baised eQTL |
| rs79271245 | chr8:40465179:T:A | - | 0.121665250828744 | 0.0308458356688652 | SARC | Female-baised eQTL |
| rs60440912 | chr8:30946113:G:C | - | 0.104724455576511 | 0.0317707617156698 | SARC | Female-baised eQTL |
| rs4733207 | chr8:30950540:C:T | - | 0.104724455576511 | 0.0317707617156698 | SARC | Female-baised eQTL |
| rs6982626 | chr8:43656344:A:G | - | -0.08070136945021 | 0.0343032785148553 | SARC | Female-baised eQTL |
| rs7462003 | chr8:43655551:C:A | - | -0.0804694333451822 | 0.0355270235047792 | SARC | Female-baised eQTL |
| rs13272907 | chr8:43652260:A:G | - | -0.0780057597354148 | 0.0417776533123831 | SARC | Female-baised eQTL |
| rs9643896 | chr8:43653060:T:G | - | -0.0776128259564731 | 0.0441753799168867 | SARC | Female-baised eQTL |
| rs12234987 | chr8:40709355:G:A | - | 0.213440075798733 | 0.0109282849803391 | LUSC | Female-baised eQTL |
| rs62642759 | chr8:40797336:T:C | - | 0.206585362291362 | 0.0196282819209574 | LUSC | Female-baised eQTL |
| rs4999666 | chr8:40763991:A:C | - | 0.213216420733759 | 0.0298504145352823 | LUSC | Female-baised eQTL |
| rs11787332 | chr8:29371119:A:G | - | 0.147813030495735 | 0.0033521137569199 | LGG | Female-baised eQTL |
| rs9643874 | chr8:40346272:G:A | - | 0.145059184047765 | 0.00481700722795116 | LGG | Female-baised eQTL |
| rs116999589 | chr8:29380035:C:T | - | 0.136510390626635 | 0.0175769374346611 | LGG | Female-baised eQTL |
| rs1362888 | chr8:41843800:C:T | - | -0.118331559177384 | 0.0342527309592696 | LGG | Female-baised eQTL |
| rs2517396 | chr8:38131787:A:C | - | -0.134970556857726 | 0.0270659065432978 | BLCA | Female-baised eQTL |
| rs16879920 | chr8:32753550:T:C | - | 0.0978577022918594 | 0.0278717023886444 | BLCA | Female-baised eQTL |
| rs16879927 | chr8:32755187:T:C | - | 0.0978577022918594 | 0.0278717023886444 | BLCA | Female-baised eQTL |
| rs16884778 | chr8:36290090:T:C | - | 0.119939527928681 | 0.0407627261747289 | BLCA | Female-baised eQTL |
| rs1425778 | chr8:41441197:A:G | - | -0.147271293396821 | 0.0478854005588536 | BLCA | Female-baised eQTL |
| rs1425779 | chr8:41441738:G:C | - | -0.147271293396821 | 0.0478854005588536 | BLCA | Female-baised eQTL |
| rs2347500 | chr8:32435562:A:G | - | 0.0825762581199101 | 0.000491741682126019 | LUAD | Female-baised eQTL |
| rs72612107 | chr8:32436836:A:C | - | 0.0801713103573082 | 0.000935387740252933 | LUAD | Female-baised eQTL |
| rs13265329 | chr8:28201295:T:C | - | -0.0458843607202457 | 0.0133245549270093 | LUAD | Female-baised eQTL |
| rs2445013 | chr8:38516304:G:C | - | 0.0441196497617718 | 0.0206009651420297 | LUAD | Female-baised eQTL |
| rs2461328 | chr8:38516875:A:G | - | 0.0441196497617718 | 0.0206009651420297 | LUAD | Female-baised eQTL |
| rs35418033 | chr8:41558671:A:T | - | 0.0349099785177497 | 0.0257167479714494 | LUAD | Female-baised eQTL |
| rs879293 | chr8:42197628:C:T | - | 0.0634127699540887 | 0.0310637677364747 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs67882526 | chr8:39533297:C:T | - | 0.098850967298615 | 0.0219894609929599 | HNSC | Male-baised eQTL |
| rs13268839 | chr8:39540213:T:C | - | 0.098850967298615 | 0.0219894609929599 | HNSC | Male-baised eQTL |
| rs7829181 | chr8:39532700:C:T | - | 0.0986697518980368 | 0.0227311999570782 | HNSC | Male-baised eQTL |
| rs1996510 | chr8:37261170:C:T | - | 0.0495476421264236 | 0.0261925969480898 | HNSC | Male-baised eQTL |
| rs12155955 | chr8:32096986:G:C | - | 0.113157424913958 | 0.0249724767724845 | THCA | Male-baised eQTL |
| rs6987535 | chr8:27848771:A:C | - | 0.0545243339323194 | 0.0302882280225011 | LIHC | Male-baised eQTL |
| rs12545052 | chr8:39730819:A:C | - | 0.0495633958198042 | 0.0486081525642229 | LIHC | Male-baised eQTL |
| rs7819030 | chr8:34604741:C:T | - | 0.0547699791211297 | 0.000317214860345031 | BLCA | Male-baised eQTL |
| rs2974297 | chr8:42516255:G:C | - | -0.0411889575077596 | 0.00927338506785341 | BLCA | Male-baised eQTL |
| rs4739513 | chr8:37503128:C:G | - | 0.0356936832486814 | 0.0133891056561471 | BLCA | Male-baised eQTL |
| rs10093400 | chr8:28068279:A:T | - | 0.0424213672443817 | 0.0436977160991384 | BLCA | Male-baised eQTL |
| rs7014045 | chr8:31147780:T:A | - | -0.0824218329831807 | 0.0139842540667998 | COAD | Male-baised eQTL |
| rs16876093 | chr8:29875137:T:G | - | -0.0756110736863292 | 0.0190784619634772 | COAD | Male-baised eQTL |
| rs2737344 | chr8:31159342:G:A | - | 0.0815797275263122 | 0.0206286173999618 | COAD | Male-baised eQTL |
| rs2737342 | chr8:31156444:G:A | - | 0.0804406753107098 | 0.0243144532678908 | COAD | Male-baised eQTL |
| rs62506103 | chr8:31159020:C:T | - | -0.0795586807559744 | 0.0277762236186605 | COAD | Male-baised eQTL |
| rs17652261 | chr8:31146927:T:C | - | -0.0757443538824591 | 0.0379170954076738 | COAD | Male-baised eQTL |
| rs6996520 | chr8:31149213:C:T | - | -0.0757443538824591 | 0.0379170954076738 | COAD | Male-baised eQTL |
| rs11574360 | chr8:31147999:C:T | - | -0.0750581130466347 | 0.0412035715140384 | COAD | Male-baised eQTL |
| rs17652297 | chr8:31146949:T:A | - | -0.0743154444500045 | 0.0492636993566322 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000104221 |
| CpG Site: cg02894896 | |
| Position to Gene: gene,promoter | |
| Male Effect: -0.0483115836124448 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg02894896 | chr8:37849203 | gene,promoter | -0.0483115836124448 | 2.24722239993308e-05 | -0.3419055559030748 | 1.993420141187854e-07 | STAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of BRF2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
